Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Shannon L. Devers is EVP, Chief Human Resources Ofc at Ionis Pharmaceuticals. OQRO lists 5 transactions filed with the SEC under this name, the latest on Oct 20, 2026, each linked to the official Form 4.
EVP, Chief Human Resources Ofc
Disclosures on record
5
Companies involved
1
Ionis PharmaceuticalsIONS
5 disclosures · Jan 2025 – Oct 2026 · 3 sold
Oct 16, 2026Sold~$59Kdisclosed Oct 20
DetailsOfficial recordOct 15, 20262,820disclosed Oct 20
DetailsOfficial recordOct 15, 20262,820disclosed Oct 20
DetailsOfficial recordSep 3, 2025Sold~$193Kdisclosed Sep 5
DetailsOfficial recordJan 16, 2025Sold~$140Kdisclosed Jan 18
DetailsOfficial recordAs of the latest filing on , Shannon L. Devers reported holding 17,811 shares of Ionis Pharmaceuticals (IONS), worth about $518K at the last close of $29 (Nov 13, 2026). In the last 12 months, Shannon L. Devers sold $59K in 1 sale.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Ionis Pharmaceuticals IONS | 17,811 | 18K direct | $29 | $518K | Oct 16, 2026 |
Is this Shannon L. Devers’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Shannon L. Devers has no open-market purchase on record since 2025. Sales in 2 of the 2 years since 2025.
Shannon L. Devers reported 0 open-market purchases and 3 sales since 2025; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | $59K1×1 trade |
| 2025 | — | $333K2×2 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Oct 16, 2026, Shannon L. Devers reported holding 17,811 shares of Ionis Pharmaceuticals (IONS). At the last close of $29 on Nov 13, 2026, that is about $518K. This is the stake disclosed in filings, not a net worth.
In SEC filings of the last 12 months, Shannon L. Devers reported 1 open-market sale worth $59K, and no open-market purchase. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
Shannon L. Devers has no open-market purchase on record since 2025. Sales in 2 of the 2 years since 2025.
In SEC filings since 2025: no open-market purchase is on record; the latest open-market sale is from 2026.
Ionis Pharmaceuticals (IONS), from 2025 to 2026: 0 purchases and 3 sales.
Shannon L. Devers reported 0 open-market purchases and 3 sales here, 2025 to 2026.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.